Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company
Abbott expects the two companies' combined dividend to equal its dividend at the time of separation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Abbott (ABT) plans to separate its global Nutrition business into an independent, publicly traded company by the end of 2027. The business has approximately $8.5 billion in annual sales and includes Similac, PediaSure, Pedialyte, Glucerna and Ensure.
Abbott intends to distribute the new company's shares to its shareholders in a transaction intended to be tax-free for U.S. federal income tax purposes. Shareholders would own both companies. Abbott expects their combined dividend to equal its dividend at separation and projects approximately $42 billion in sales for the remaining Abbott business.
Completion requires regulatory approvals, an effective Form 10 registration statement and final board approval. Abbott expects one-time transaction charges before separation. The planned separation will not affect its 2026 guidance or the 2027 guidance it plans to provide in January.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Planned Nutrition separation would give Abbott shareholders shares in both independent, publicly traded companies.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Sales growth and margin profile are expected to improve for Abbott after separation.
- Minor point. Forward-looking: it has not happened yet and may not happen.U.S. federal income tax-free treatment is intended for the separation.
- Minor point. Forward-looking: it has not happened yet and may not happen.Combined dividend is expected to equal Abbott's dividend at the time of separation.
- Minor point. Forward-looking: it has not happened yet and may not happen.2026 and forthcoming 2027 guidance will not be affected by the planned separation.
Negative
- Minor pointRegulatory approvals, effective Form 10 and final board approval remain conditions for completion expected by end-2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.One-time transaction charges are expected during the periods preceding separation.
Details
Market move: ABT -3.37% vs previous close. Nutrition business separation
On Oct 21, the day this news came out, the latest delayed price for ABT is 3.37% below the previous close. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $99.00. Relative volume is exceptionally heavy at 176.2x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Nutrition business annual sales
- Approximately $8.5 billion
- Profile of the planned independent company
- Abbott sales after separation
- Approximately $42 billion
- Expected profile after the transaction
- Expected completion
- By the end of 2027
- Subject to customary conditions, regulatory approvals, Form 10 effectiveness and board approval
Key Terms
tax-free separation financial
registration statement regulatory
form 10 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies
- The new Nutrition company will be a global leader in the rapidly growing healthy nutrition market, with a portfolio of iconic, category-leading brands, including Similac, PediaSure, Pedialyte, Glucerna and Ensure
- Abbott will have accelerated sales growth and an expanded margin profile
- Abbott intends to separate its Nutrition business through a tax-free distribution to Abbott shareholders
- Separation expected to be completed by the end of 2027
ABBOTT PARK, Ill., Oct. 21, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced its intention to separate its Nutrition business into an independent, publicly traded company that will be a global leader in the rapidly expanding healthy nutrition market with approximately
"As we continue to shape Abbott for the future, this separation will benefit both companies, setting each one up for maximum success in its respective market," said Robert B. Ford, chairman and chief executive officer, Abbott. "Our Nutrition business has a unique opportunity to capitalize on the growing demand for healthy nutrition, and it will be better positioned as an independent company to more effectively direct its strategic resources across its priorities. At the same time, Abbott's core higher-growth, innovation-driven portfolio of medical devices, diagnostics and established medicines has compelling growth opportunities to improve the health and lives of people around the world."
With different investment identities and requirements, growth profiles, and innovation cycles, both companies will benefit from resource and capital allocation strategies aligned to their distinct business models.
Nutrition: A leading healthy nutrition company
The Nutrition company will be a global leader in healthy nutrition with approximately
As an independent company, it will be better positioned to focus its resources more strategically across innovation, commercial activities and key initiatives that advance performance and long-term value creation.
Its portfolio of iconic global brands with leadership positions across infant, pediatric, medical and adult nutrition is highly differentiated in its competitive set and backed by evidence-based scientific research and healthcare professional recommendation, which drives durable organic growth at scale across channels. Abbott's Nutrition portfolio is anchored by category-leading brands, including Ensure, the world's No. 1 adult nutrition supplement drink; PediaSure, the world's No. 1 pediatric nutrition supplement; Glucerna, the world's No. 1 diabetes management nutrition brand; and Similac, the No. 1 infant formula brand in the
The Nutrition business has continued to innovate its portfolio – underpinned by consumer preferences and trends – with 10 product launches in the first half of 2026, including a high-protein Ensure shake featuring 42 grams of protein, the first and only ready-to-feed liquid infant formula made with whole milk in the
Daniel Salvadori, executive vice president and group president, Established Pharmaceuticals and Nutritional Products, will become chief executive officer of the new Nutrition company. Mr. Salvadori joined Abbott in 2014 and has successfully led complex international businesses, as senior vice president, Established Pharmaceuticals,
Abbott: A fast-growing global health leader
Abbott will remain one of the largest, fastest growing and most diversified healthcare companies with unique breadth and scale. After the transaction, Abbott will have sales of approximately
The company remains aligned with evolving and durable healthcare trends, including an aging population, growing prevalence of chronic disease, personalized treatment and greater demand for earlier diagnosis so people can stay and get healthy. Abbott will maintain a balanced portfolio of products and payors with a strong presence across both developed and emerging markets.
Transaction Details
Abbott intends to separate the Nutrition business through a distribution of shares of the independent Nutrition company to Abbott shareholders. Upon completion of the separation, Abbott shareholders will own shares in both Abbott and the independent Nutrition company.
Abbott expects the combined dividend to be paid by Abbott and the new Nutrition company to be equal to Abbott's dividend at the time of separation. The transaction is intended to qualify as a tax-free separation for
Abbott expects to complete the transaction by the end of 2027, subject to customary conditions, including regulatory approvals, the effectiveness of a registration statement on Form 10 and final approval by the Abbott Board of Directors.
The planned separation will not impact Abbott's guidance for 2026 or the guidance for 2027 that Abbott plans to provide in January. Abbott expects to incur one-time charges related to the transaction during the periods preceding the separation, to be quantified at a later date.
The Nutrition business will continue to operate as part of Abbott throughout the separation process.
Goldman Sachs & Co. LLC is serving as financial advisor to Abbott, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel to Abbott.
Abbott Conference Call
Abbott will discuss the transaction on its third-quarter earnings conference call today at 8 a.m. Central time (9 a.m. Eastern time). The webcast will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later today.
Frequently Asked Questions
Why is Abbott intending to separate its nutrition business?
Abbott has a successful history of shaping the company through internal and external actions that deliver on evolving growth opportunities.
We regularly examine the makeup of the company, and it is clear that the Nutrition business has a unique opportunity to capitalize on consumer preferences and trends in healthy nutrition. As an independent company, it will be better positioned to focus its resources more strategically across innovation, commercial activities and key initiatives that advance performance and long-term value creation. At the same time Abbott will focus on its core higher-growth, innovation-driven portfolio of medical devices, biowearables, diagnostics and established pharmaceuticals, which has compelling opportunities to expand health impact for people around the world.
With different investment identities and requirements, growth profiles and innovation cycles, both companies will benefit from resource and capital allocation strategies aligned to their distinct business models.
What will the profile of the new Nutrition company be after the separation?
The new Nutrition company will be a global leader in healthy nutrition with approximately
What will Abbott look like after the separation?
Abbott remains one of the largest, fastest growing and most diversified healthcare companies with unique breadth and scale. It will have sales of approximately
When will the separation be complete?
Abbott expects to complete the transaction by the end of 2027, subject to customary conditions, including regulatory approvals, the effectiveness of a registration statement on Form 10 and final approval by the Abbott Board of Directors.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube.
Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including statements regarding the planned separation of the Nutrition business from Abbott and the expected financial results and prospects of Abbott and the new Nutrition company following the separation. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements, and there is no assurance as to the timing of the planned separation or whether it will be completed. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Additional factors relating to the planned separation, including the ability to satisfy the conditions necessary to complete the transaction, obtain applicable regulatory approvals and tax rulings, successfully separate the businesses, and realize the expected benefits of the transaction, may also cause actual results to differ materially from those indicated in the forward-looking statements. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
View original content:https://www.prnewswire.com/news-releases/abbott-announces-its-intention-to-separate-its-global-nutrition-business-into-an-independent-publicly-traded-company-302915339.html
SOURCE Abbott
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.